These positive trial results led to approval of nivolumab by the FDA in advancedsquamous and nonsquamous NSCLC as second-line systemic therapy after progression onfirst-line chemotherapy, regardless of PD-L1 expression (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.